Market Overview

UPDATE: Jefferies Downgrades HealthSouth Corporation to Hold on Regulatory Headwinds

Related HLS
Healthsouth 8-K Reaffirms 2015 Guidance
Benzinga's M&A Chatter for Monday August 31, 2015

Jefferies lowered its HealthSouth Corporation (NYSE: HLS) rating from Buy to Hold and reduced its price target from $25 to $23.

Jefferies noted, "HLS's strong Q2 performance and raised guidance was impressive, but we recommend taking advantage of stock strength to lighten long positions, fearing that IRF reimbursement could get greater scrutiny later this year when legislators look for funding offsets to another doc fix and deficit reduction."

HealthSouth Corporation closed at $22.93 on Thursday.

Latest Ratings for HLS

Oct 2015BarclaysMaintainsEqual-weight
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015JMP SecuritiesUpgradesMarket PerformOutperform

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (HLS)

Get Benzinga's Newsletters